SARM SR9011 CAS 1379686-30-2 Pharmaceutical Raw Material for
1. SR9011 Quick detail:
Cas No 1379686-29-9
Molucelar weight 479.03524
2. SR9011 COA:
|Appearance||An odorless, almost white or white powder||pass|
The retention time of the major peak is
confirm to the RS
|Loss on Drying||Not more than 0.5%||0.33%|
|Assay(HPLC)||Not less than 99.0%||99.59%|
|Ignition residue||Not more than 0.1%||pass|
|Heavy metal||Not more than 20 ppm|
3. SR9011 Description
SR9011 is a trifunctional methacrylate monomer that provides
exceptional adhesion to metal
SR9011 is recommended for use in peroxide cured coatings, sealants,
and PVC-based plastisols.
Usage levels of 5% to 10% by weight are recommended.
SR9011 is a potent and specific synthetic REV-ERB. It also has good
in vivo plasma/brain exposure.
The nuclear receptors REV-ERB-α and REV-ERB-β play an integral role
in regulating the expression
of core clock proteins, driving rhythms in activity and metabolism.
Administration of SR9011 alters
circadian behavior and the circadian pattern of core clock gene
expression in the hypothalami of mice.
The circadian expression pattern of an array of metabolic genes in
the liver, skeletal muscle and
adipose tissue was also altered, resulting in increased energy
expenditure. Treatment of diet-induced
obese mice with SR9011 decreased obesity by reducing fat mass and
markedly improved dyslipidaemia and hyperglycaemia. These results
indicate that synthetic REV-ERB ligands that pharmacologically
the circadian rhythm may be beneficial in the treatment of sleep
disorders as well as metabolic diseases.
4. How to Use SR9011
In vitro: SR9011 was used at 5-10 μM concentration in vitro and in
In vivo: IP administration of SR9011 was used at 100 mg/kg once or
twice per day for 12-30
days in different mouse models.
6. SARMS We offer
|AICAR||2627-69-2||acts by entering nucleoside pools, significantly increasing levels
adenosine during periods of ATP breakdown
|MK2866||841205-47-8||medical prescription for prevention of cachexia, atrophy, and
and for Hormone or Testoserone Replacement Therapy.
|MK-677||15972-10-0||A growth hormone secretagogue, treatment of obesity, a promising
for the treatment of frailty in the elderly
|LGD-4033||1165910-22-4||pharmacological profile similar to that of enobosarm,
|GW1516||317318-70-0||For obesity, diabetes, dyslipidemia and cardiovascular disease|
|Andarine(S4)||401900-40-0||partial agonist, intended mainly for treatment of benign prostatic|
|SR9009||1379686-30-2||under development at The Scripps Research Institute (TSRI),
the level of metabolic activity in skeletal muscles of mice
|SR9011||1379686-30-2||For obesity, diabetes, dyslipidemia and cardiovascular disease|
|RAD140||1182367-47-0||New generation for gaining mass and cutting edges|
|YK11: a SARM and myostatin inhibitor in one|
|GHRP-2||158861-67-7||Growth Hormone Releasing Peptide-2|
|GHRP-6||87616-84-0||Growth Hormone Releasing Peptide-6|
|TB500||107761-42-2||Thymosin beta 4|